Optimizing the use of biological therapy in patients with inflammatory bowel disease

Biological therapy revolutionized the treatment of inflammatory bowel disease (IBD) during the last decade. These monoclonal antibodies, which target tumor necrosis factor (TNF), integrins or IL12/23, have been approved—or are in development for—both Crohn’s disease (CD) and ulcerative colitis (UC)....

Descripción completa

Detalles Bibliográficos
Autor principal: Moss, Alan C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2015
Materias:
Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4324872/
https://www.ncbi.nlm.nih.gov/pubmed/25567472
http://dx.doi.org/10.1093/gastro/gou087

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4324872/
https://www.ncbi.nlm.nih.gov/pubmed/25567472
http://dx.doi.org/10.1093/gastro/gou087

Ejemplares similares